Donepezil and α-synuclein Constipation: A Longitudinal Study
In a case study, four patients with -synuclein or Lewy body disorders were diagnosed at various stages of their illness. In persons with Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies, the acetylcholinesterase inhibitor (AChEI) Donepezil was used to treat symptoms of constipation, obstipation, and impaction (NCDLB). Obstipation is characterised as severe constipation with bowel motions occurring only once or twice a week. Donepezil was connected to a significant reduction in symptom severity in all four individuals, which was sustained at six, twelve, eighteen, thirty-six, and forty-eight month intervals with no apparent loss in bowel motility or the introduction of new symptoms. According to the findings, the AChEI Donepezil can assist people with -synuclein disorders reduce their constipation, obstipation, and impaction symptoms over time.
Charles M. Lepkowsky
Independent Practice, 1143 Deer Trail Lane, Solvang, CA 93463-9519, United States.